Dipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system

Current Cardiology Reports

Volumn 15, Issue 8, 2013, Pages

  Solun, B ^a   Marcoviciu, D ^a   Dicker, D ^a  

^a HASHARON HOSPITAL   (Israel)

Author keywords

Cardiovascular disease; Dipeptidyl peptidase 4; Incretin; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); CARDIOVASCULAR DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84879404228     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-013-0382-2     Document Type: Article

References (63)

1. Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13:S1-68.
2. Hocher B, Reichetzeder C, Alter ML. Renal and Cardiac Effects of DPP-4 Inhibitors-from Preclinical Development to Clinical Research. Kidney Blood Press Res. 2012;36:65-84.
3. Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther. 2008;88:1322-35.
4. Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res. 2012;9:109-16.
5. Bayliss WM, Starling EH. On the causation of the so-called 'peripheral reflex secretion' of the pancreas. Proceedings of the Royal Society of London[Biol];
6. Moore B, Edie ES, Abram JH. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem J. 1906;1:28-38.
7. Dupre J, Ross SA, Watson D, et al. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 1973;37:826-8.
8. Yoder SM, Yang Q, Kindel TL, et al. Stimulation of incretin secretion by dietary lipid: is it dose dependent? Am J Physiol Gastrointest Liver Physiol. 2009;297:G299-305.
9. Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2:1300-4. (Pubitemid 17156636)
10. Guillausseau PJ, Meas T, Virally M, et al. Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab. 2008;34 Suppl 2:S43-8. (Pubitemid 351982036)
11. Burcelin R, Knauf C, Cani P. Pancreatic alpha-cell dysfunction in diabetes. Diabetes Metab. 2008;34 Suppl 2:S49-55.
12. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32 Suppl 2:S157-63.
13. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011;124(1 Suppl):S3-18.
14. Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009;297:127-36.
15. Gaba M, Singh S, Gaba P. Dipeptidyl peptidase-4 inhibitors: a new approach in diabetes treatment. Int J Drug Dev Res. 2009;1:146-56.
16. Matteucci E, Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem. 2009;16:2943-51.
17. Green BD, Flatt PR, Bailey CJ. Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes. Expert Opin Emerg Drugs. 2006;11:525-39. (Pubitemid 44386374)
18. Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012;344:e1369.
19. Gupta V, Kalra S. Choosing a gliptin. Indian J Endocrinol Metab. 2011;15:298-308.
20. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011;71:1441-67.
21. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010;12:648-58.
22. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012;51:501-14.
23. Mukai E, Fujimoto S, Inagaki N. Severe hypoglycemia by combination therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and sulfonylureas. Nihon Rinsho. 2011;69:907-11.
24. Gallwitz B. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. Handb Exp Pharmacol. 2011;203:53-74.
25. Abu-Hamdah R, Rabiee A, Meneilly GS, et al. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009;94:1843-52.
26. Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagonlike peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004;110:955-61. (Pubitemid 39128621)
27. Ossum A, van Deurs U, Engstrøm T, et al. The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart. Pharmacol Res. 2009;60:411-7.
28. Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide-1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54:146-51. (Pubitemid 40105106)
29. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemiareperfusion injury in rat heart. Regul Pept. 2008;146:243-9.
30. Timmers L, Henriques JPS, de Kleijin DPV, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009;53:501-10.
31. Buteau J, Roduit R, Susini S, et al. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia. 1999;42:856-64. (Pubitemid 29325077)
32. Siragusa M, Katare R, Meloni M, et al. Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice. Circ Res. 2010;106:757-68.
33. Iwasa M, Kobayashi H, Yasuda S, et al. Antidiabetic drug voglibose is protective against ischemia-reperfusion injury through glucagons-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway in rabbits. J Cardiovasc Pharmacol. 2010;55:625-34.
34. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58:975-83.
35. Iwasa M, Yamada Y, Kobayashi H, et al. Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits. Br J Pharmacol. 2011;164:119-31.
36. Panjwani N, Mulvihill EE, Longuet C, et al. GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE-/-Mice. Endocrinology. 2013;154:127-39.
37. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33:187-215.
38. Askari AT, Unzek S, Popovic ZB, et al. Effect of stromal-cellderived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet. 2003;362:697-703. (Pubitemid 37101067)
39. Saxena A, Fish JE, White MD, et al. Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction. Circulation. 2008;117:2224-31.
40. Tang J, Wang J, Song H, et al. Adenovirus-mediated stromal cellderived factor-1 alpha gene transfer improves cardiac structure and function after experimental myocardial infarction through angiogenic and antifibrotic actions. Mol Biol Rep. 2010;37:1957-69.
41. Lenski M, Kazakov A, Marx N, et al. Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol. 2011;51:906-18.
42. Ye Y, Keyes KT, Zhang C, et al. The myocardial infarct sizelimiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol. 2010;298:H1454-65.
43. Sauvé M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes. 2010;59:1063-73.
44. Read PA, Khan FZ, Heck PM, et al. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3:195-201.
45. Kubota Y, Miyamoto M, Takagi G, et al. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci. 2012;27:1364-70.
46. Matsubara J, Sugiyama S, Sugamura K, et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol. 2012;59:265-76.
47. Ta NN, Schuyler CA, Li Y, et al. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2011;58:157-66.
48. Briand F, Thieblemont Q, Burcelin R, et al. Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETPapoB100 transgenic mice. Diabetes Obes Metab. 2012;14:662-5.
49. Ferreira L, Teixeira-de-Lemos E, Pinto F, et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm. 2010;2010:592760.
50. Matikainen N, Mänttäri S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. 2006;49(9):2049-57. (Pubitemid 44168471)
51. Pacheco BP, Crajoinas RO, Couto GK, et al. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens. 2011;29:520-8.
52. Girardi AC, Fukuda LE, Rossoni LV, et al. Dipeptidyl peptidase IV inhibition downregulates Na+-H+exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol. 2008;294:F414-22. (Pubitemid 351199407)
53. Mistry GC, Maes AL, Lasseter KC. etal. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48(5):592-8. (Pubitemid 351503521)
54. Ogawa S, Ishiki M, Nako K, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med. 2011;223(2):133-5.
55. Krijnen PA, Hahn NE, Kholová I, et al. Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients. Basic Res Cardiol. 2012;107:1-13.
56. Gupta AK, Verma AK, Kailashiya J, et al. Sitagliptin: Anti-platelet effect in diabetes and healthy volunteers. Platelets. 2012;23:565-70.
57. Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110:826-33.
58. Bethel MA, Green J, Califf RM, et al. Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) 69th Scientific Sessions of the American Diabetes Association: New Orleans. LA, June. 2009(5-9).
59. Scirica BM, Bhatt DL, Braunwald E, et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J. 2011;162:818-25.
60. Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol. 2012;11:6.
61. Johansen OE, Neubacher D, von Eynatten M, et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012;11:3.
62. Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380:475-83.
63. White WB, Bakris GL, Bergenstal RM, et al. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011;162:620-6.